Observational Study on Cognitive Decline in Intracerebral Hemorrhage
This study is looking at how silent brain infarcts (SBIs) – small areas of brain damage seen on scans – might affect thinking and memory in people who have had a spontaneous intracerebral hemorrhage (sICH), which is a type of bleeding in the brain. Researchers want to see if SBIs are linked to lower cognitive (thinking) abilities, faster cognitive decline, certain brain imaging findings, and higher inflammation levels in the blood. You would have cognitive tests, MRI scans of your brain, and blood draws. The study aims to enroll 118 participants aged 18 to 80 who have experienced a primary intracerebral hemorrhage and do not have pre-existing dementia. The study's success would mean understanding if SBIs are a clear indicator for future cognitive problems.
- Study design
- This is an observational study planning to enroll 118 participants. It is not a treatment study, but rather observes changes over time.
- What's involved
- You would undergo cognitive testing, MRI scans, and blood draws during your hospitalization and at 3, 6, and 12 months after your sICH.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for global cognition for up to 12 months after hospitalization.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Biomarkers for Cognitive Decline in Intracerebral Hemorrhage
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Rajeev Garg, MD · PRINCIPAL_INVESTIGATOR · Rush University Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Global CognitionFrom date of randomization and assessed throughout the during hospitalization for qualifying ICH event up to 12 months
Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery
- Global Cognition3 months after hospitalization
Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery
- Global Cognition6 months after hospitalization
Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery
- Global Cognition12 months after hospitalization
Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery
- Absolute volumetric change in White Matter Hyperintensity (WMH)from MRI at hospitalization to MRI at 12 months
Uses a novel imaging analysis algorithm on serial 3-Tesla brain MRI
- Serum soluble urokinase-type plasminogen activator receptor (suPAR) levelsFrom date of consent and assessed during hospitalization for qualifying ICH event up to 12 months
compare SuPAR levels between the silent brain infarct (SBI) positive and the SBI negative groups
- Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels3 months after hospital discharge
compare SuPAR levels between the silent brain infarct (SBI) positive and the SBI negative
- Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels6 months after hospital discharge
compare SuPAR levels between the silent brain infarct (SBI) positive and the SBI negative
- Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels12 months after hospital discharge
compare SuPAR levels between the silent brain infarct (SBI) positive and the SBI negative